COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,220 Articles (22,733 medRxiv, 8,487 bioRxiv)

Most recent first Previous |  Page 3120: Articles 31191-31200  | Next

Insights into Cross-species Evolution of Novel Human Coronavirus 2019-nCoV and Defining Immune Determinants for Vaccine Development
Ramaiah, A., Arumugaswami, V.
10.1101/2020.01.29.925867 — Posted: 2020-01-30 Discussion: Onsite
Estimating the effective reproduction number of the 2019-nCoV in China
Cao, Z., Zhang, Q., Lu, X., Pfeiffer, D., Jia, Z., Song, H., Zeng, D. D.
10.1101/2020.01.27.20018952 — Posted: 2020-01-29 Discussion: Onsite
Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines
Liu, X., Wang, X.-J.
10.1101/2020.01.29.924100 — Posted: 2020-01-29
Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening
Li, Y., Zhang, J., Wang, N., Li, H., Shi, Y., Guo, G., Liu, K., Zeng, H., Zou, Q.
10.1101/2020.01.28.922922 — Posted: 2020-01-29 Discussion: Onsite
The incubation period of 2019-nCoV infections among travellers from Wuhan, China
Backer, J. A., Klinkenberg, D., Wallinga, J.
10.1101/2020.01.27.20018986 — Posted: 2020-01-28 Discussion: Onsite | Offsite
Epidemiological identification of a novel infectious disease in real time: Analysis of the atypical pneumonia outbreak in Wuhan, China, 2019-20
Jung, S.-m., Kinoshita, R., Hayashi, K., Linton, N. M., Yang, Y., Akhmetzhanov, A. R., Nishiura, H.
10.1101/2020.01.26.20018887 — Posted: 2020-01-28
Epidemiological characteristics of novel coronavirus infection: A statistical analysis of publicly available case data
Linton, N. M., Kobayashi, T., Yang, Y., Hayashi, K., Akhmetzhanov, A. R., Jung, S.-m., Yuan, B., Kinoshita, R., Nishiura, H.
10.1101/2020.01.26.20018754 — Posted: 2020-01-28 Discussion: Onsite | Offsite
Beware of asymptomatic transmission: Study on 2019-nCoV prevention and control measures based on extended SEIR model
Shao, P., Shan, Y.
10.1101/2020.01.28.923169 — Posted: 2020-01-28
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., Ying, T.
10.1101/2020.01.28.923011 — Posted: 2020-01-28 Discussion: Onsite
Nelfinavir was predicted to be a potential inhibitor of 2019 nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation
Xu, Z., Peng, C., Shi, Y., Zhu, Z., Mu, K., Wang, X., Zhu, W.
10.1101/2020.01.27.921627 — Posted: 2020-01-28 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).